PolyVascular develops a biocompatible, polymer-based transcatheter pulmonary valve and delivery system specifically designed for children as young as 2 years old, minimizing the need for open-heart surgeries. This technology addresses the risks associated with animal tissue valves and human donor grafts, allowing for a safer, less invasive treatment option that supports a healthier lifestyle for pediatric patients.
Funding
Funding not disclosed
Founders
Product
Problem
Children with congenital heart defects often require multiple open-heart surgeries, which can hinder their development and quality of life. Current treatment options, such as animal tissue valves, carry risks of endocarditis, while human donor grafts may trigger immune responses.
Solution
PolyVascular offers a biocompatible, polymer-based transcatheter pulmonary valve and delivery system designed specifically for young children. This minimally invasive solution reduces the need for open-heart surgeries, allowing children as young as two years old to live healthier lives. The polymer valve addresses the limitations of animal and human tissue valves by providing a durable and easily manufactured alternative that minimizes the risk of complications. The valve is delivered percutaneously using a system designed for accurate placement in pediatric patients.
Target Audience
The primary target audience includes pediatric cardiologists and hospitals specializing in the treatment of congenital heart defects in young children.
Features
- Biocompatible, polymer-based valve material designed for durability and reduced risk of complications.
- Transcatheter delivery system enabling minimally invasive valve placement.
- Valve sizes suitable for children as young as two years old.
- Percutaneous delivery method, reducing the need for open-heart surgery.
- Designed to minimize the risk of endocarditis and immune sensitization.
- Easy-to-use delivery system for accurate valve positioning.